Astellas to File NDA for Enzalutamide in Japan in 1st Half of FY2013

Yoshihiko Hatanaka, president of Astellas Pharma revealed at an earnings briefing on May 14 that the company aims to file a new drug application (NDA) for its anticancer drug enzalutamide (brand name in the US: XTANDI)in Japan in the first...read more